While continuous B-cell aplasia indicates persistence and functionality of CD19-CAR-T cells, patients with B-cell reconstitution at early time after CAR T cell treatment (prior to 6 months post infusion) tend to have a significantly increased risk for CD19+ leukemia recurrence [2,149,163]. Here, CD19 is linked to leukemia.